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Matrix metalloproteases (MMPs) play important roles
in normal and pathological remodeling processes
including atherothrombotic disease, inflammation,
angiogenesis, and cancer. MMPs have been viewed
as matrix-degrading enzymes, but recent studies
have shown that they possess direct signaling capa-
bilities. Platelets harbor several MMPs that modulate
hemostatic function and platelet survival; however
their mode of action remains unknown. We show
that platelet MMP-1 activates protease-activated
receptor-1 (PAR1) on the surface of platelets. Expo-
sure of platelets to fibrillar collagen converts the
surface-bound proMMP-1 zymogen to active MMP-1,
which promotes aggregation through PAR1. Unex-
pectedly, MMP-1 cleaves PAR1 at a distinct site that
strongly activates Rho-GTP pathways, cell shape
change and motility, and MAPK signaling. Blockade
of MMP1-PAR1 curtails thrombogenesis under arte-
rial flow conditions and inhibits thrombosis in animals.
These studies provide a link between matrix-depen-
dent activation of metalloproteases and platelet-G
proteinsignalingand identifyMMP1-PAR1asapoten-
tial target for the prevention of arterial thrombosis.
INTRODUCTION
Myocardial infarction due to rupture of atherosclerotic plaques is
a leading contributor to morbidity and mortality in the United
States, Europe, and other industrialized nations. Acute plaque
rupture exposes subendothelial collagen, which promotes
platelet activation and formation of a potentially occlusive
thrombus at the site of vascular damage (Ruggeri, 2002).
Following their initial tethering to subendothelial collagen and
matrix proteins, activation of transiently adhered platelets by
autocrine mediators is critical for propagation of the platelet
thrombus. Reinforcement of the transient adhesive contacts by
activating G protein-dependent shape change, granule release,332 Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc.and integrins permits growth of a stable thrombus that is resistant
to thehigh shear stress of arterial blood flow (Jackson et al., 2003;
Moers et al., 2003). Drugs that target the secondary autocrine
mediators of platelet thrombus formation, such as aspirin and
thienopyridines, have proven to be beneficial; however, many
patients taking these drugs still sustain thrombotic events and
might benefit from new therapeutics that interfere with matrix-
dependent platelet activation (Bhatt and Topol, 2003).
Matrix metalloproteases have recently emerged as important
mediators of platelet function and vascular biology. Initially
described as extracellular matrix remodeling enzymes involved
in tissue repair and cancer invasion, a renewed focus has
centered on MMPs and the related metalloprotease disintegrins
because of their prominence in vascular wall inflammation (Dol-
lery and Libby, 2006) and thrombotic thrombocytopenic purpura
(Levy et al., 2001). Endogenous platelet metalloproteases have
been shown to damage platelet function by cleaving cell-surface
receptors, and broad-spectrum metalloprotease inhibitors have
been shown to improve post-transfusion recovery of platelet
concentrates (Bergmeier et al., 2003; Stephens et al., 2004).
Platelets express several metalloproteases including MMP-1,
MMP-2, MMP-3, and MMP-14 on their surface (Chesney et al.,
1974; Galt et al., 2002; Kazes et al., 2000; Sawicki et al., 1997).
Notably, endogenous MMP-1 and MMP-2 can actually promote
platelet aggregation, but the cell surface target(s) and mecha-
nism of activation have not been elucidated (Galt et al., 2002;
Sawicki et al., 1997). A recent study that examined the effects
of MMP-1 promoter polymorphisms in 2000 patients found
a significantly increased risk of myocardial infarction in patients
with high promoter activity haplotypes and a significantly
decreased risk in patients with low promoter activity haplotypes
(Pearce et al., 2005). Moreover, serum levels of MMP-1 and
MMP-13 were found to be highly elevated in the culprit coronary
artery relative to peripheral blood of patients with acute myocar-
dial infarction (Suzuki et al., 2008), raising the question ofwhether
MMPs are directly involved in arterial thrombosis.
It was recently shown that the G protein-coupled receptor,
PAR1, is directly cleaved and activated on the surface of cancer
cells by fibroblast-derived MMP-1 (Boire et al., 2005). PAR1 is
the major thrombin receptor of human platelets (Leger et al.,
2006b) and is an important mediator of platelet aggregation
following tissue factor (TF)-dependent generation of thrombin
(Mackman, 2004). However, under pathophysiologic conditions
of acute plaque rupture, exposed collagen is the most efficient
stimulus of the critical early events of platelet recruitment and
propagation under arterial flow that could trigger metallopro-
tease activation on the platelet surface.
In this study, we set out to explore a metalloprotease-depen-
dent pathway of platelet thrombogenesis through PAR1. We
found that exposure of platelets to collagen caused activation
of MMP-1, which in turn directly cleaved PAR1 on the surface
of platelets. Unexpectedly, MMP-1 cleaved the N-terminal extra-
cellular domain of PAR1 at a distinct site from the thrombin
cleavage site. This cleavage event generated a longer tethered
peptide ligand that was an agonist of platelet activation and
PAR1 signaling. Blocking the MMP1-PAR1 pathway inhibited
collagen-dependent thrombogenesis, arterial thrombosis, and
clot retraction, suggesting that therapeutics that target this met-
alloprotease-receptor system could be an orthogonal strategy in
treatment of patients with acute coronary syndromes.
RESULTS
Collagen Generates Active MMP-1 that Cleaves
the N-terminal Domain of PAR1 on Platelets
Studies from the1970s (Chesney et al., 1974) showed that human
platelets contain significant amounts of collagenase activity that
could be released upon exposure to various agonists. More
recent studies (Galt et al., 2002) identified themajor platelet colla-
genase asMMP-1 and found thatMMP-1 could prime the aggre-
gatory response to other agonists and cause redistribution of
the b3 integrins to the cell periphery; however, the mechanism
of action of MMP-1 remained unknown. We set out to determine
whether the pro-aggregatory effects of platelet MMP-1 were
mediated by the PAR1 receptor.
We measured the amount of in situ activation of endogenous
proMMP-1 on the platelet surface following stimulation with the
primary agonist collagen versus the secondary mediators ADP
and thromboxane. Stimulation of platelets with collagen led to
the release of the platelet collagenase activity into the supernatant
(Figure 1A). Cleavage of a fluorogenic collagen substrate was
completely blocked by the MMP-1 inhibitor, FN-439. Blocking
antibodies against MMP-1 also completely inhibited the platelet
collagenase activity released by collagen, whereas blocking anti-
bodies against the two other collagenases, MMP-8 and MMP-13,
or IgG control had no effect. Stimulation of gel-filtered platelets
with ADP or the thromboxane mimetic, U-46619, however,
resulted in amajority of theMMP-1 collagenase activity remaining
bound to the platelet. Treatment of washed platelets with collagen
but not ADP or U-46619 led to efficient release of the proMMP-1
domain (and/or proMMP-1) as assessed by ELISA using anti-
bodies that recognized the pro-domain of MMP-1 (Figure 1B).
FACS analysis confirmed thatMMP-1 is expressed on the surface
of resting platelets that could be released by exposure to collagen
(Figure1C). The lectinconvulxin,which ligandsspecificallywith the
GPVI/FcgRcollagen receptor (Nieswandt andWatson, 2003), also
caused full release of the proMMP-1 domain from the platelet
surface (Figure 1B). Thus, collagen fibrils per se are not necessary
for the release of proMMP-1 from the platelet surface, and other
strong platelet agonists may trigger the release mechanism.Thebindingsite(s) for theplatelet-associatedproMMP-1arenot
known. One candidate is the a2b1 collagen receptor as previous
studies showed specific interactions between proMMP-1 and
a2b1 on human keratinocytes and astrocytes (Conant et al.,
2004; Dumin et al., 2001). Coimmunoprecipitation experiments
indicated that proMMP-1 forms a stable complex with the a2b1
integrin on platelets (Figure 1D). MMP-1 (predominantly the pro
form) was also found to associate with the aIIbb3 integrin, as sug-
gestedbypreviousconfocalmicroscopystudies (Galt et al., 2002).
Conversely, proMMP-1 did not associate with GPIba or GPVI.
Therefore, proMMP-1 is likely to be preassociated with both
collagen and fibrinogen integrins in resting platelets.
The ability of collagen to activate significant amounts of endog-
enous MMP-1 collagenase activity on the surface of platelets
would lead to the prediction that PAR1 may be cleaved in either
an autocrine or paracrinemanner following exposure to collagen.
Using a monoclonal antibody raised against the amino-terminal
thrombin cleavage peptide region of PAR1, residues 32–46, we
assessed the relative abilities of thrombin, MMP-1, and collagen
to cause cleavage of platelet PAR1. As shown in Figure 1E, incu-
bation of platelets with thrombin or MMP-1 was able to cause
release of the N-terminal cleavage peptide of PAR1 into the
supernatant, which was blocked by hirudin or FN-439, respec-
tively. MMP-3 and MMP-7 were not able to cause release of
the PAR1N-terminal peptide (Figure S1A available online). Treat-
ment of the resting platelets with collagen led to the release of the
N-terminal peptide that was blocked by FN-439 or an MMP-1-
blocking antibody (Ab) but not by hirudin (Figures 1E and S1B).
Furthermore, ADP or U-46619 were also able to cause release
of the N-terminal peptide of PAR1 albeit at lower efficiency
(Figure S1C). Blockade of either the P2Y12 ADP receptor with
AR-C69931MX (ARC) or thromboxane with aspirin (ASA) had no
effect on the collagen-dependent release of the PAR1N-terminal
peptide (Figure S1D). Together, these data provide direct
evidence that the endogenously generated MMP-1 collagenase
activity is able to cleave PAR1 on the surface of human platelets
independently of thrombin.
Identification of the MMP-1 Cleavage Site on PAR1
Studies have demonstrated that serine proteases such
as thrombin, plasmin, and APC directly hydrolyze PAR1
at LDPR41YS42FL (P4P3P2P1YP1
0P20P30) to generate the
S42FLLRN-tethered ligand (TRAP), which activates PAR1 in an
intramolecular mode (Kuliopulos et al., 1999; Seeley et al.,
2003; Vu et al., 1991). However, matrix metalloproteases such
as MMP-1 generally prefer a hydrophobic amino acid at the
P10 site, a basic or hydrophobic amino acid at P20, and a small
residue (alanine, glycine, or serine) at P30 (Netzel-Arnett et al.,
1991; Turk et al., 2001). Therefore, MMP-1 may not efficiently
cleave at the R41YS42FL thrombin site. To identify the MMP-1
cleavage site, we synthesized a 26 amino acid peptide (TR26,
PAR1 residues 36–61) corresponding to the N-terminal domain
of PAR1, which contained the thrombin cleavage site and flank-
ing regions (Figures 2A and 2B). Incubation of the TR26 peptide
with thrombin yielded the expected cleavage peptide, TR20
(residues 42–61), as determined by mass spectrometry. In
contrast, incubation of the TR26 peptide with MMP-1 yielded
TR22, which corresponds to PAR1 residues 40–61 (Figures 2ACell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc. 333
Figure 1. CollagenGeneratesActiveMMP-1
on Platelets that Cleaves the PAR1 N-Ter-
minal Extracellular Domain
(A) Human platelets (106/ml) were treated for 15min
with either 20 mM ADP, 20 mM U-46619, or 20 mg/
ml type-I collagen. The enzymatic activity (mean ±
standard deviation [SD], n = 3) of active MMP-1 in
supernatants and platelet lysates was determined
using DQ collagen I as fluorogenic substrate in
the presence or absence of 3 mM FN-439, or
20 mg/ml each of MMP1-blocking Ab or control
IgG, with APMA-activated MMP-1 serving as
control (striped bars).
(B) Pellets and supernatants were collected from
platelets (250,000/ml) stimulated with the agonists
in (A) or convulxin (1 mg/ml). Concentrations of
released and platelet-associated MMP-1 pro-
domains were measured by ELISA (mean ± SD,
n = 3).
(C) Surface expression of total platelet MMP-1
determined by flow cytometry. Dashed gray line:
secondaryantibodyalone; solid lines: FACSprofiles
of platelets treated with the indicated concentra-
tionsof collagen for 15minat 37Cand then stained
with primary (AB806) plus secondary antibodies.
(D) Association of proMMP-1 with integrins in
resting human platelets. Lysates from gel-filtered
platelets were incubated with 4–5 mg/ml anti-a2,
-b1, -b3, -GPVI, -GPIBa, or mouse IgG control for
2–4 hr at 4C. Protein G sepharose was added
and incubated for an additional 1 hr. Beads were
collected andwashed four times in lysis buffer sup-
plemented with 200 mM NaCl. Western analyses
were conducted using a polyclonal Ab against
the C terminus of MMP-1 (AB8105) or the hinge
region (AB806), which gave similar results.
(E) MMP-1 and collagen cause release of an
N-terminal thrombin cleavage fragment from the
extracellular domain of PAR1. Gel-filtered platelets
were treated for 10 min with thrombin (3 nM),
MMP-1 (3 nM), or collagen (5 mg/ml) in the pres-
ence or absence (PBS buffer) of 0.00013 U hirudin
or 5 mM FN-439 at 37C. Supernatants were
concentrated 20-fold and applied to nitrocellulose
membranes, then probed with the IIaR-A mono-
clonal antibody. The PAR1 N-terminal thrombin
cleavage peptide (A26-R41) andPAR1 flexible linker
peptide (N-acetyl-T67-L84-C) served as positive
and negative controls (100 ng), respectively.and 2B). This indicates that MMP-1 cleaves the PAR1 exodo-
main at LD39YP40RSFL, a site which is located 2 amino acid
residues to the N-terminal side of the thrombin cleavage site at
R41-S42.
Toverify the locationof this putativeMMP-1cleavagesite in the
full-length receptor, we mutated the critical P10 residues of both
the MMP-1 and thrombin cleavage sites and measured the
effects of these mutations on cleavage rates of T7-tagged
receptor. To inhibit cleavagebyMMP-1,we replaced theputative
P10 proline with asparagine (P40N PAR1), a substitution that
had previously been shown to reduce cleavage of a1 collagen
peptides to less than 10% (Berman et al., 1992). To inhibit prote-
olysis by thrombin, we mutated the P10 serine of the thrombin
cleavage site to aspartate (S42D PAR1), a mutation that was334 Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc.anticipated to suppress cleavage by thrombin (Chang, 1985).
The P40N PAR1 mutant was fully cleaved by thrombin but was
poorly cleaved by MMP-1 using two independent sources of
MMP-1 (Figures 2C, 2D, and S2A). Conversely, the S42D PAR1
mutant was substantially cleaved by MMP-1 but was poorly
cleaved by thrombin. Identical results were seen for cleavage of
a mutant TR26-P40N peptide that was cleaved at the R41-S42
bond by thrombin but was not cleaved by MMP-1 (Figure 2A).
Functional studies validated the relative cleavage specificities
of the P40N and S42D mutants for thrombin and MMP-1.
Thrombin was able to fully activate Rho signaling and chemo-
tactic migration in MCF-7 cells expressing the P40N mutant but
had negligible activity for the S42D mutant (Figures 2E and 2F).
Conversely, MMP-1 was able to induce Rho signaling and
Figure 2. MMP-1 Activates PAR1 by
Cleaving the Receptor at a Cryptic Ligand
Site
(A) Identification of the MMP-1 cleavage site on
the TR26 N-terminal peptide region of PAR1.
Synthetic 26-mer peptides encompassing the
thrombin cleavage site region from the N-terminal
domain of PAR1, TR26 (A36-S61) or TR26-P40N
(A36-K61), were incubated with 10 nM thrombin,
10 nM MMP-1 (APMA activated, purified from
human fibroblasts), or PBS buffer for 10 min at
37C. Peptide cleavage mixtures were separated
by RP-HPLC and cleavage products identified by
MALDI-mass spectroscopy as described (Kulio-
pulos et al., 1999).
(B) MMP-1 and thrombin cleavage sites on the
PAR1 extracellular domain and PAR1 peptide
agonists.
(C and D) Cleavage of PAR1 N-terminal extracel-
lular mutants by thrombin and MMP-1. COS7 cells
transiently transfected with T7-tagged WT, P40N,
or S42D PAR1 were incubated for 30 min at 37C
in PBS with 0.3–30 nM thrombin (C) or APMA-acti-
vated MMP-1 (D). Loss of T7 epitope (mean ± SD,
n=3)wasanalyzedby flowcytometry asdescribed
(Kuliopulos et al., 1999).
(E) Activation of Rho by thrombin and MMP-1
cleavage site mutants. MCF-7 cells (PAR1 null)
were transiently transfected with T7-tagged WT,
S42D, or P40N PAR1 for 48 hr and then stimulated
with 10 nM thrombin, 10 nM MMP-1, or PBS
buffer for 15 min at 37C. Rho-GTP present in
cell lysates (mean ± SD, n = 3) was measured as
described (Kaneider et al., 2007).
(F) Chemotactic migration of MCF-7 cells express-
ing thrombin and MMP-1 cleavage site mutants.
MCF-7 cells transfected with the PAR1 cleavage
mutants were allowed to migrate overnight toward
DMEM/0.1% BSA (buffer) plus 3 nM thrombin or
3 nM MMP-1 in a Transwell apparatus (8 mm
pore). Cells that migrated toward the bottom side
of the membrane were counted and expressed
as % relative to WT PAR1 and thrombin (mean ±
SD, n = 3).chemotaxis in MCF-7 cells expressing the S42D mutant but had
little activity toward the P40N mutant. MMP-1 (0.3–10 nM) was
not able to detectably cleave T7-tagged PAR2, PAR3, or PAR4
expressed on COS7 cells (Figures S2B–S2D). Together, these
cleavage and signaling data indicate that MMP-1 specifically
activates PAR1 by cleaving at LD39YP40RSFL rather than at the
LDPR41YS42FL thrombin cleavage site and does not cleave the
other PARs.
Activation of PAR1 Signaling with the MMP1-Generated
Tethered Ligand
MMP-1 cleavage of PAR1 at LDYP40RS will generate a longer
tethered ligand, P40RSFLLRN–, than that produced by thrombin
(Seeley et al., 2003). To provide further evidence that MMP1-
generated tethered ligand could activate PAR1, we tested the
ability of the synthetic peptide, PR-SFLLRN (PR-TRAP), to stim-
ulate PAR1 signaling. PR-TRAP was a full agonist of PAR1-
dependent Rho and p38 MAPK signaling in platelets (Figures3A and 3B). Addition of the PAR1 antagonist, RWJ-56110,
completely blocked signaling induced by PR-TRAP. We also
determined that the PR-TRAP ligand activated platelet shape
change, a critical early event in platelet activation that is medi-
ated by G12/13-Rho signaling (Huang et al., 2007; Offermanns
et al., 1994). PR-TRAP-induced platelet shape change was
completely blocked by the PAR1 antagonist, RWJ-56110
(Figure 3C). We tested two other peptides for agonist activity
that would be generated by putative cleavage at the flanking
peptide bonds: the R-TRAP peptide corresponding to cleavage
at LDP40YR41SFLLRN and the DPR-TRAP peptide correspond-
ing to cleavage at L38YD39PRSFLLRN (Figure 2B). The R-TRAP
peptide retained partial agonist activity for PAR1-dependent
platelet shape change, whereas the DPR-TRAP peptide had
nearly no activity (Figure 3C). Likewise, the control peptide,
RP-TRAP, in which the first two amino acid residues were
reversed, did not stimulate Rho or p38 MAPK nor platelet shape
change (Figures 3A–3C).Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc. 335
We then confirmed that exogenously added MMP-1 was able
to activate PAR1-dependent signaling in platelets. MMP-1 (3 nM)
was able to stimulate Rho-GTP activity to the same extent as
equimolar thrombin (Figure 4A). MMP-1 was also able to elicit
platelet shape change, calcium mobilization, and aggregation
that was inhibited by the PAR1 antagonist, RWJ-56110 (Figures
4B–4D). Exogenously added MMP-1 also activated phospho-
p38 MAPK and its substrate, MAPKAP-K2, in an activity profile
similar to thrombin (Figures 4E and 4F). MAPKAP-K2 phosphor-
ylates the small heat shock protein HSP27 involved in cytoskel-
etal reorganization, further suggesting that MMP-1 may play
a role in the initial events leading to platelet shape change and
help prime platelets for aggregation.
Collagen Triggers p38 MAPK Signaling, Rho Activation,
and Platelet Aggregation through MMP1-PAR1
We tested whether pharmacologic blockage of metalloproteases
or PAR1 would have an effect on collagen-dependent platelet
aggregation. Soluble type I fibrillar collagen stimulated platelet
aggregationwithanEC50of 5mg/ml. Inhibitionofmetalloproteases
with the zinc-chelating agent 1,10-phenanthroline resulted in
80% loss of aggregation to 5 mg/ml collagen (Figure 5A). Likewise,
the broad spectrum metalloprotease hydroxamate inhibitor,
MMP-200 (IC50 = 7 nM for MMP-1, 2.3 nM for MMP-2, 135 nM
Figure 3. Agonist Function of the MMP1-
Generated Peptide Ligand of PAR1 in Plate-
lets
(A) The PRSFLLRN peptide (PR-TRAP) induces
PAR1-dependent RhoA activation in platelets.
Gel-filtered human platelets, supplemented with
0.3 mg/ml fibrinogen, were treated with 0.2%
DMSO vehicle, or 10 mM SFLLRN (TRAP), PR-
TRAP, or reversed peptide (RP-TRAP), for 5 min
at 37C in presence or absence of 1 mM RWJ-
56110 as indicated. Platelets were lysed and
Rho-GTP and total Rho were determined by
western analysis. Data are the mean ± SD.
(B) PR-TRAP activates p38 MAPK in platelets.
Platelets were stimulated with different TRAP
peptides as indicated for 5 min at 37C. Western
blots of p38 MAPK activity with phospho-specific
p38 MAPK antibody or total p38MAPK antibody
were then performed.
(C) PR-TRAP induces platelet shape change.
Washed human platelets were pretreated with
2 mM EGTA and then treated with the indicated
agonists in the presence or absence of 1 mM
RWJ-56110 while stirring at 1100 rpm. The
decrease in light transmittance is an indication of
the platelet shape change reaction.
for MMP-3, 10–100 nM for MMP-7, 1–10
nM for MMP-13), caused a significant
50%–60% inhibition of collagen-initiated
aggregation. Treatment with the MMP-1
inhibitor, FN-439, inhibited collagen-
induced aggregation to the same extent
as MMP-200. Conversely, inhibitors
against MMP-8, MMP-9, and MMP-13
had no effect on collagen-induced aggregation (data not shown).
The specific thrombin inhibitor hirudin or the broad-spectrum
serine protease inhibitor, PPACK, hadnoeffect oncollagenaggre-
gation (Figure 5A). PAR1 was inhibited by three orthogonal
approaches to evaluate its contribution to collagen-dependent
aggregation. The small-molecule inhibitor RWJ-56110 or
a PAR1-blocking antibody attenuated 50% of collagen (5 mg/ml)
induced aggregation, the same extent as the MMP-1 inhibitor.
Likewise, the cell-penetrating PAR1 pepducins, P1pal-12
and P1pal-7, which inhibit PAR1 signaling to intracellular G
proteins (Boire et al., 2005; Covic et al., 2002; Kaneider et al.,
2007), gave identical levels of inhibition as blocking MMP-1
(Figure 5A). Inhibition of the PAR4 thrombin receptor with the
P4pal-10 pepducin (3 mM) had only a slight (10%) effect on
collagen-induced aggregation.
Collagen is known to induce p38 stress-activated protein
kinase (MAPK) pathways in human platelets though the mecha-
nismremainsunclear (Kuliopuloset al., 2004).Additionofcollagen
caused robust phosphorylation of p38 MAPK (Figure 5B). The
collagen (5 mg/ml) induced phospho-p38MAPK signal was effec-
tively blocked by the PAR1 and MMP-1 inhibitors, but not with
inhibitors againstMMP-8,MMP-9/13, or thrombin.We also found
that collagen-dependent activation of the p38 MAPK substrate,
MAPKAP-K2, was dependent on both PAR1 and MMP-1.336 Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc.
Figure 4. MMP1-PAR1 Signaling and Activation of Platelets
(A) MMP-1 efficiently activates Rho-GTP in platelets. Gel-filtered human platelets were exposed to 3 nM thrombin or 3 nM APMA-activated MMP-1 as indicated
for 5 min at 37C and Rho-GTP and total Rho determined by western analysis.
(B) MMP-1 induces platelet shape change. Washed human platelets were pretreated with 2 mM EGTA and then challenged with MMP-1 in the presence or
absence of 1 mM RWJ-56110 while stirring at 1100 rpm.
(C) MMP-1 induces PAR1-dependent calcium fluxes in platelets. Calcium fluxmeasurements of gel-filtered platelets following challenge with MMP-1 in the pres-
ence or absence of RWJ-56110 were performed at 25C as described (Kuliopulos et al., 1999).
(D) Platelet aggregation is induced by MMP-1. Gel-filtered platelets were challenged with MMP-1 in the presence or absence (0.2% DMSO vehicle) of the PAR1
inhibitor 1 mM RWJ-56110.
(E and F) MMP-1 efficiently activates PAR1-dependent MAPK signaling in platelets. Gel-filtered platelets were challenged with the indicated concentrations of
thrombin (Thr) or MMP-1 for 5 min as in (A) and p38MAPK (E) or downstream MAPKAP-K2 (F) activation was quantified by densitometry of western blots using
a phospho-p38MAPK or phospho-MAPKAP-K2 antibody, respectively. Data are the mean ± SD of three experiments.Collagen activation of phospho-MAPKAP-K2was blocked by the
PAR1 antagonists RWJ-56110 and P1pal-7 and by FN-439 but
not by MMP8 inh (data not shown). Collagen caused robust acti-
vation of Rho-GTP that was attenuated by 75% with antagonists
against PAR1 and MMP-1, but not by inhibitors or blocking anti-
bodies against MMP-8, MMP-9/13, or thrombin (Figures 5C and
5D). However, at saturating levels of collagen (20 mg/ml) sufficient
to elicit full aggregation of platelets, none of the PAR1 norMMP-1
inhibitors had a major effect (%25%) on collagen-dependent
aggregation, the phospho-p38MAPK signal, or Rho-GTP activity
(Figure S3A–S3D), indicating that the MMP1-PAR1 pathway can
be bypassed at super-EC50 levels of collagen. To address
whether the observed MMP-1 effects were due to secondary
secretion of ADP or thromboxane after collagen stimulation, we
inhibited the P2Y12 ADP response with ARC and thromboxanewith aspirin. Treatment of platelets with either ARC or aspirin
had no effect on the ability of 5 or 20 mg/ml collagen or 10 nM
MMP-1 to activate Rho-GTP (Figures 5D and S3D) or phospho-
p38 MAPK, but the inhibitors could still suppress aggregation to
collagen (Figures S3A and S3C). In contrast, blockade of the
MMP1-PAR1 pathway nearly completely inhibited activation of
p38 andRho-GTP to 5 mg/ml collagen (Figure 5B–5D). This would
indicate that at EC50 collagen exposure,MMP1-PAR1 is essential
for activationof p38 andRho-GTP, and important for aggregation,
whereas the secondary ADP and thromboxane pathways do not
activatep38andRho-GTPatany rangeof collagenconcentration.
At saturating collagen, the ADP and thromboxane contributions
appear to compensate for the MMP1-PAR1 pathway in platelet
aggregation via mechanisms that do not involve p38 or Rho-
GTP signaling.Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc. 337
Early Platelet Thrombus Formation on Collagen
Surfaces Is Promoted by MMP-1 and PAR1
Activation of platelets in ruptured atherosclerotic plaques occurs
under high shear-stress conditions on subendothelial surfaces
enriched in collagen fibrils. We examined whether initial forma-
tion and propagation of platelet-platelet thrombi on collagen
surfaces was affected by blocking MMP-1 or PAR1. Whole
human blood was anticoagulated with heparin and perfused
over collagen-coated surfaces at arterial flow rates of 1000 s1.
Treatment with either MMP-1 or PAR1 inhibitors did not affect
the primary adhesion of platelets to the immobilized collagen
fibrils. However, the growth rate and size of platelet aggregate
‘‘strings’’ was significantly attenuated by 75%with the MMP-1
inhibitor, FN-439, or the PAR1 blocking agents P1pal-12,
P1pal-7, or RWJ-56110 (Figures 6A and 6C). By comparison,
aspirin pretreatment had little or no effect on the growth of the
platelet thrombi. This result is consistent with thromboxane play-
ing a relatively minor role in thrombogenesis under arterial shear-
stress conditions (Jackson et al., 2003) as compared to the
MMP1-PAR1 pathway.
Figure 5. PharmacologyofCollagen-MMP1-
PAR1-Dependent Aggregation, MAPK, and
Rho Signaling in Platelets
Gel-filtered platelets from healthy individuals (sup-
plemented with 0.3 mg/ml fibrinogen) were chal-
lenged with 5 mg/ml collagen in the presence or
absence (0.2% DMSO vehicle) of the indicated
inhibitors. Platelets were preincubated for 5 min
with the thrombin inhibitors PPACK (200 mM) or hir-
udin (1 U/ml), the Zn-chelator 1,10-phenanthroline
(1,10-PA; 100 mM), the broad spectrummetallopro-
tease inhibitor MMP-200 (200 nM), the MMP-1
inhibitor FN-439 (3 mM), the PAR1 ligand binding
site inhibitor RWJ-56110 (1 mM), the PAR1 SFLLR-
blocking antibody (75 mg/ml), the PAR1 pepducins
P1pal-12 (3mM)orP1pal-7 (3mM), thePAR4pepdu-
cin P4pal-10 (3 mM), MMP-8 inhibitor (25 nM), or
MMP-9/13 inhibitor (10 nM).
In (A) platelet aggregation was monitored by light
transmittance. In (B), platelets were treated as in (A)
and then lysed with Laemmli sample buffer 5 min
after addition of collagen. p38 MAPK activity was
then assessed by western blot. In (C), platelets
were treated as in (B) and then Rho GTP activity
was assessed by western blot. In (D) platelets were
pretreated with various blocking Abs for 2 hr or
inhibitors (ARC, 0.5 mM P2Y12 antagonist AR-
C69931MX; ASA, 1mMaspirin for 30min) and stim-
ulated with either 5 mg/ml collagen, 10 nM MMP-1
(Calbiochem), or 10 nM MMP-1 from a second
source (S2, BioMol) as indicated and Rho-GTP
activity assessed as in (C). Representative blots are
shown at the bottom of (B)–(D). Data are the
means±SDof threeexperiments. *p<0.01,#<0.05.
Collagen-activated platelets also
provide a pro-coagulant surface and
produce tissue factor that aids in the
production of thrombin (Giesen et al.,
1999; Mackman, 2004). To evaluate
whether MMP1-PAR1 activation of early platelet thrombi forma-
tion is also relevant under conditions in which thrombin activity is
not inhibited, we conducted the arterial flow experiments in the
presence of corn trypsin inhibitor (CTI), which blocks factor
XIIa and the contact pathway of coagulation but does not inhibit
thrombin generation in whole blood (Mann et al., 2007). The
results using the CTI anticoagulant were very similar to those
conducted with heparin. Inhibition of MMP-1 or PAR-1 signifi-
cantly attenuated the size of the platelet micro-thrombi on the
collagen surfaces, whereas addition of the thrombin inhibitor,
hirudin, had no effect (Figures 6B and 6D). Again, aspirin
pretreatment of the CTI whole blood did not affect the extent
of platelet-thrombi formation on the collagen surfaces. Thus,
under conditions of arterial shear stress, MMP1-PAR1 signifi-
cantly promotes early thrombogenesis on collagen surfaces.
Next, we used clot retraction assays to examine the potential
role of MMP-1 on the structure of large platelet-rich clots over
time. Platelet receptors trigger clot retraction by activating
myosin-dependent contraction of the cytoskeleton, which is in
turn connected to the extracellular matrix (fibrinogen) via focal338 Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc.
adhesions. We found that the MMP-1 inhibitor, FN-439,
completely inhibited clot formation and retraction induced by
2.5–5 mg/ml collagen (Figure S4). Blockade of PAR1 with RWJ-
56110 gave a nearly identical pattern of inhibition, whereas the
negative control MMP9/13 inhibitor had negligible effects over
the whole collagen titration. Therefore, MMP-1 and PAR1 play
a significant role in the formation and retraction of large
platelet-rich thrombi initiated by collagen.
Systemic Platelet Activation and Arterial Thrombosis by
MMP-1 and PAR1 in Guinea Pig
Weexaminedwhether blocking theMMP1-PAR1 pathwaywould
protect against collagen-mediated systemic platelet activation
in vivo.Guineapigs serveasa relevantmodel to test platelet func-
tion because like humans they also express PAR1 on their plate-
lets (Leger et al., 2006a), and guinea pig MMP-1 shares 90%
identity with human MMP-1 (Huebner et al., 1998). We first
confirmed that guinea pig platelets express proMMP-1 on their
surface by FACS analysis and that addition of collagen causes
release of collagenase activity that is completely blocked by
either FN-439 or a MMP1-neutralizing Ab (Figures S5A and
S5B). Likewise, inhibition of MMP-1 or PAR1 gave 35%–50%
suppression of aggregation and complete inhibition of Rho-
GTP activity in response to 10 mg/ml collagen in guinea pig
platelets (Figures S5C and S5D), which was consistent with the
previous results using human platelets. Intravascular platelet
activation was then induced by an intravenous injection of
collagen into the guinea pigs. The infused collagen caused
a severe drop in mean systemic platelet counts from a baseline
level of 309,000 ± 50,000/ml to 194,000 ± 20,000/ml. Strikingly,
pre-administration of the PAR1 pepducin, P1pal-7, almost
completely protected against collagen-induced thrombocyto-
penia in theguineapigs (Figure 6E). TheMMP-1 inhibitor, FN-439,
also afforded significant protection against intravascular platelet
activation.
To assess the efficacy of blockade of MMP-1 and PAR1 on
arterial thrombosis, we used a standard carotid artery FeCl3
injury model in guinea pigs. FeCl3 causes denudation of the
artery and exposure of type I collagen and other subendothelial
matrix proteins. Intravenous administration of the PAR1 antago-
nist, P1pal-7, gave a significant 50% prolongation of the mean
occlusion time (Figure 6F). Administration of the MMP-1 antago-
nist, FN-439, gave a similar prolongation of the mean arterial
occlusion time. Co-administration of the PAR1 and MMP-1
inhibitors did not lead to further prolongation of the mean occlu-
sion time, consistent with MMP-1 acting in the same pathway as
PAR1. Lastly, collagen zymography revealed that the platelet-
rich clot isolated from injured carotid arteries of vehicle-treated
animals (veh clot) had significant MMP-1 activity that comigrated
with APMA-activated MMP-1 and with the MMP-1 activity from
the supernatants of collagen-activated platelets (Figure 6G).
Conversely, resting platelets (control) from whole blood or arte-
rial thrombi from animals treated with the MMP1 inhibitor
(FN439 clot) did not contain active MMP-1. These data, together
with the previous results, indicate that inhibition of MMP1-PAR1
may provide substantial protection against collagen-dependent
platelet activation and acute arterial thrombosis in animals.DISCUSSION
Matrixmetalloproteases have longbeen implicated in the chronic
proinflammatory and tissue-remodeling events leading to
cleavage of interstitial collagen and development of vulnerable
atherosclerotic plaques (Sukhova et al., 1999). Although patho-
anatomic studies of human atherosclerotic lesions suggest that
large plaques can cause ischemic symptoms, the key contrib-
uting factor to themorbidity andmortality associatedwith athero-
sclerosis is excessive platelet thrombus formation on exposed
collagen surfaces following acute plaque rupture (Ruggeri, 2002).
In the present study, we discovered a collagen-initiated
pathway of thrombogenesis that is mediated by the autocrine
actionofplateletMMP-1on thePAR1 receptor.Exposureofplate-
lets to collagen caused robust activation ofMMP-1 on the platelet
surface, which in turn directly cleaved and activated PAR1 inde-
pendently of thrombin. These studies provide a link between
matrix-dependent activation of metalloproteases and platelet
G protein signaling and identify MMP1-PAR1 as a potential target
for the prevention of arterial thrombosis.
Unexpectedly, MMP-1 cleaved PAR1 at a distinct site in its
extracellular domain, which generated a longer tethered ligand
than that produced by thrombin. The MMP1-cleaved receptor
or soluble peptide analog strongly stimulatedG12/13-Rho-depen-
dent pathways, chemotaxis, andMAPK signaling in platelets and
other cells. The MMP-1 cleavage site on PAR1 aligned with an
optimized MMP-1 cleavage site motif determined from mixture-
based oriented peptide libraries (Turk et al., 2001) and by
substrate cleavage studies (Berman et al., 1992; Netzel-Arnett
et al., 1991). Mutation of respective P10 residues uncoupled
MMP-1 from thrombin cleavage and generated PAR1 receptors
that exhibited protease-specific activity.
Collagen signaling in human platelets through the a2b1 and
GPVI/FcgR collagen receptors is not well understood but has
been shown to be partly dependent on G protein signaling
through autocrine stimulation of ADP and thromboxane recep-
tors (Jackson et al., 2003). Blockade of the P2Y12 Gi-coupled
ADP receptor inhibits collagen-dependent thrombogenesis
under arterial flow conditions, thus establishing an important
role for downstream ADP-Gi signaling. Thromboxane activates
theGq andG12/13-coupled TXA2 receptor; however, aspirin failed
to prevent thrombogenesis on collagen surfaces under arterial
shear stress and does not prevent occlusive thrombus formation
in patients with severe arterial stenosis (Veen et al., 1993). The
current studies show that MMP-1 is a potent activator of PAR1-
G12/13 pathways involved in platelet shape change and Rho acti-
vation and thus would synergize with P2Y12-Gi signaling.
Blockade of MMP-1 or PAR1 with pharmacologic inhibitors
significantly attenuated thrombogenesis on collagen surfaces
under arterial shear-stress conditions and thrombosis in animals.
As compared to MMP-1 inhibition, antagonism of thrombin had
little effect on early thrombogenesis on the collagen surfaces
under high arterial flow rates. Indeed, several studies have previ-
ously shown that thrombin may bemore important for later prop-
agation and stability of platelet thrombi and is not involved in
initiating early thrombus growth at high arterial shear stress
(Fressinaud et al., 1992; Gast et al., 1994; Inauen et al., 1990)
unless tissue factor levels are extremely high (Okorie et al.,Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc. 339
Figure 6. Platelet MMP-1 and PAR1 Promote Early Thrombus Formation under Arterial Shear-Stress Conditions and Arterial Thrombosis in
Guinea Pig
(A and C) Pharmacologic blockade of MMP-1 or PAR1 inhibits early micro-thrombus formation on collagen surfaces in the presence of heparin. Normal whole
blood from humans anticoagulated with heparin (10 U/ml) was pretreated for 10 min with vehicle (0.2% DMSO), MMP-200 (200 nM), MMP-1 inhibitor FN-439
(3 mM), PAR1 inhibitor RWJ-56110 (1 mM), or PAR1 pepducins P1pal-12 or P1pal-7 (3 mM) or for 30 min with 1 mM aspirin prior to the assay as indicated. Blood
was then perfused over a glass slide coated with fibrillar collagen type I under an arterial shear rate of 1000 s1. The mean area of formed thrombus was deter-
mined at 7 min. Area measurements in (C) represent the mean ± standard error of the mean (SEM) of three separate experiments from five different blood donors.
(B and D) Pharmacologic blockade of MMP-1 or PAR1 inhibits early platelet micro-thrombus formation on collagen surfaces independently of thrombin. Whole
blood was anticoagulated with CTI (30 mg/ml) to block the contact pathway, otherwise the experiments were conducted identically as in (A). Hirudin was used as
indicated at 0.0013 U/ml.
(E) P1pal-7 and FN-439 protect against collagen-induced systemic platelet activation in guinea pigs. Vehicle, P1pal-7 (3 mg/kg) or FN-439 (10 mg/kg) were deliv-
ered i.v. to the internal jugular vein of guinea pigs (n = 6) and allowed to circulate for 10 min. Blood was drawn before and 10 min after collagen induction of
systemic activation of platelets. Data are the mean ± SEM.
(F) Blockade of PAR1 and/or MMP-1 inhibits occlusion of carotid arteries in guinea pigs. Vehicle (), P1pal-7 or FN-439 (n = 4–5) was administered through the
jugular vein with the indicated concentrations 10 min prior to FeCl3 injury of the carotid artery as described in the Experimental Procedures. Data are the mean ±
SEM; *p < 0.05.
(G) Detection of MMP-1 activity in guinea pig platelet supernatents and arterial clots. Platelets were isolated from guinea pigs and stimulated with 20 mg/ml
collagen for 15 min and platelet supernatants and pellets, or whole resting platelets (control), were prepared and collagen zymography or immunoblots with
MMP1-Ab (AB806) were performed. Arterial clots were also removed from the Fe-Cl injured carotid arteries from animals (n = 5) treated with FN-439 (FN439340 Cell 137, 332–343, April 17, 2009 ª2009 Elsevier Inc.
2008). Likewise, thrombin inhibitors such as heparin have incom-
plete effects on platelet thrombus formation at high arterial flow
rates but have a more prominent inhibitory effect on the growth
and overall stability of platelet thrombi at low and intermediate
shear rates (Inauen et al., 1990). Unlike direct blockade of
MMP-1or thrombin, downstream inhibitionofPAR1might impact
both the initialMMP1-dependent events of platelet thrombi prop-
agation on blood vessel collagen and later thrombin-dependent
propagation and stabilization and could prove beneficial in pre-
venting arterial thrombosis in acute settings.
EXPERIMENTAL PROCEDURES
Materials
ProMMP-1 (R90% purity, from human synovial fibroblasts), proMMP-3,
proMMP-7, FN-439 (MMP inh-1), MMP8 inh, and MMP9/13 inh were from Cal-
biochem. MMP-200 was obtained from Enzyme Systems Products. RWJ-
56110 was a gift from Johnson & Johnson and AR-C69931MX was from Astra
Zeneca. The pepducins, P1pal-12, P4pal-10, and P1pal-7, and other peptides
were synthesized with C-terminal amides and purified by RP-HPLC as before
(Covic et al., 2002). The IIaR-A monoclonal antibody that reacts to the amino-
terminal thrombin cleavage peptide of PAR1was fromBiodesign. A solid phase
proMMP-1 ELISA system from R&D Systems (Quantikine DMP100) detects
proMMP-1 and soluble pro-domain but does not detect active MMP-1. The
MMP-1 blocking Ab (AB8105) recognizes both pro and active forms of MMP-1
but does not cross-react with other MMP family members (Chemicon). The
MMP-8 (IM38L) and MMP-13 (IM44L) blocking Abs were from Oncogene, the
anti-a2 (Gi9 or AK7), b1 (MAB1987), b3 (MAB1957) were from Chemicon, GPVI
(SC20149)was fromSantaCruz, andGPIBa (MM2/174)was fromAbDSerotec.
Platelet Aggregation Studies
Phlebotomy was performed on 20 healthy volunteer donors following informed
consent procedures established by the IRB of Tufts Medical Center. Platelets
fromplatelet-richplasma (PRP)were isolatedbygel filtration using aSepharose
2B (Pharmacia) in modified PIPES buffer in the presence of 1 mM EDTA and
0.1 U/ml of apyrase as described (Kuliopulos et al., 1999). Alternatively, whole
blood was obtained from Hartley Sprague guinea pigs (drawn from the vena
cava) into 3% citrate plus 10 U/ml heparin. Washed platelets from the guinea
pigs were prepared in PIPES buffer. Platelet aggregation was measured with
a Chronolog 560VS/490-2D aggregometer as before (Kuliopulos et al., 1999).
Dot Blot Detection of the N-Terminal PAR1 Cleavage Peptide
Gel-filtered platelets were exposed to different agonists in the presence or
absence of 5 mM FN-439 or 0.01 U hirudin for 10 min at 37C in a reaction
volume of 250 ml. Reactions were terminated by centrifugation to remove the
platelets from the supernatant. Supernatants were collected and concentrated
20-fold by slow evaporation in a Speed Vac; concentrated supernatants were
then applied as a 10 ml spot on nitrocellulose membranes. Membranes were
dried at room temperature for 30 min and then probed with the IIaR-A mono-
clonal antibody.
Molecular Biology
Human PAR1 was cloned into pcDEF3 as described previously (Kuliopulos
et al., 1999) and was used for generating all mutants. The PAR1 mutants
P40N and S42D were generated using the Quick Change Site-Directed Muta-
genesis kit (Stratagene) and sequenced to verify the fidelity of themutagenesis.
MMP-1 Activity Assays
Human or guinea pig platelets from PRP were concentrated 4-fold by centrifu-
gation at 700 g for 25 min at room temperature and then resuspended in0.25 volume of PIPES containing 1 mM EDTA (final platelet count was 109/ml).
Platelets were treated with PBS (buffer), 20 mMADP, 20 mMU-46619, or 20 mg
collagen in the presence of 2.5 mM CaCl2. The platelets were incubated for
15 min at 37C with occasional gentle mixing. Platelets were collected by
centrifugation at 10,000 g for 5 min at 4C and resuspended in lysis buffer
(50 mM Tris HCl, 100 mM NaCl, 1 mM NaF, 5 mM EDTA, 0.1% (v/v) Triton
X-100, 100 mM PMSF, pH 7.4) and then sheared with a 27 gauge needle.
Supernatants and platelet pellets were separated by centrifuging the lysate
at 12,000 g for 2 min. DQ Collagen type I (Molecular Probes) was employed
as fluorescent reporter of collagenase activity as described (Boire et al.,
2005). Collagen zymography was performed as described previously (Gogly
et al., 1998). In brief, samples were resolved in 8% polyacrylamide gels
containing (1 mg/ml) calf skin type I collagen (Sigma). After electrophoresis,
gels were washed (30 min) twice in regeneration buffer followed by incubation
in developing buffer (48 hr) and stained with 0.25% Coomassie brilliant blue
G-250 and then destained.
Thrombus Growth Assays under Arterial Flow Conditions
A flow chamber (Glycotech) with type-I fibrillar collagen-coated glass slides
was mounted on the stage of an IMT-2 inverted microscope (Olympus) equip-
ped with Retiga 1300 digital camera (QImaging) and 403 objective. One of
the flow chamber inlets was connected to a syringe pump (Harvard Apparatus)
calibrated to create a shear rate of 1000 s1. Normal human blood was antico-
agulated with 10 U/ml of heparin, or with corn trypsin inhibitor (CTI, 30 mg/ml
final). Whole blood was pretreated with various pharmacologic inhibitors for
5 min and then perfused over the collagen-coated glass slide. After 2–15
min of perfusion, blood was removed from the flow chamber by gentle
displacement with PIPES buffer and images of 8–10 fields were acquired
using OpenLab software (Improvision) and analyzed using NIH Image 1.63
software.
Systemic Platelet Activation and Arterial Thrombosis in Guinea Pig
Animal experiments were performed in accordance with the NIH guidelines
and approved by the Tufts IACUC. Two- to four-week-old Hartley guinea
pigs (170–260 g) were anesthetized by intraperitoneal (i.p.) injection of xyla-
zine (10 mg/kg) plus ketamine (50 mg/kg) and then catheterized via the left
jugular vein and injected (200 ml) with either vehicle (20% DMSO/80% water),
P1pal-7, or FN-439. For determination of collagen-dependent systemic
platelet activation, 10 min after administration of inhibitors, 200 mg collagen
in 200 ml of PBS was delivered via the jugular vein. Ten minutes after collagen
injection, blood was collected into sodium citrate (0.3% v/v final) from the
contralateral jugular vein and platelet counts were measured with a Hema-
vet850. For arterial thrombosis experiments, 10 min after intravenous (i.v.)
administration of inhibitors, the right carotid arteries were injured for 20 min
using a 24 mm2 piece of Bio-Rad Trans-Blot paper soaked in 20% FeCl3.
Arterial flow 5 mm distal to the site of injury was measured with a 0.5 V
Doppler probe (Transonic Systems). An arterial occlusion was defined as
a flow rate of <0.01 V for R5 min.
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